PPP Schedule

Lauren Osborne, MD 
Associate Professor, Obstetrics & Gynecology
Associate Professor, Psychiatry
Vice Chair, Clinical Research in Obstetrics & Gynecology
Weill Cornell Medicine

Dr. Osborne graduated from Weill Cornell Medical College and received her psychiatric training at Columbia University/New York State Psychiatric Institute. She completed both clinical and research fellowships in women's mental health, and is an expert on the diagnosis and treatment of mood and anxiety disorders during pregnancy, the postpartum, the premenstrual period, and perimenopause. Dr. Osborne is an Associate Professor of OB-GYN and of Psychiatry and serves as the Vice Chair of Clinical Research in the Department of Obstetrics & Gynecology at Weill Cornell Medicine. Her research on perinatal mental illness focuses on models of care and on biological mechanisms and biomarkers, with a focus on neurosteroids and the immune system, and she runs the PIPPI Lab – Psychoneuroimmunology in Pregnancy and Postpartum – at Weill Cornell. Dr. Osborne’s clinical work consists of collaborative care for perinatal mental health within OB/GYN. She is also the President-Elect of Marcé of North America; founder and chair of the National Curriculum in Reproductive Psychiatry, a free web-based standardized curriculum; and an editor of The APA Textbook of Women’s Reproductive Mental Health. Her work has been supported by the Brain and Behavior Foundation, the Doris Duke Foundation, the American Board of Psychiatry and Neurology, the Department of Defense, the NIMH, and the NICHD.

Jay Fournier, PhD | Optimizing Recovery: Comprehensive Care Pathways for Depression at The OSU Depression Recovery Center 
Clinical Psychologist
Associate Professor, The Ohio State University
Director, Mood and Anxiety Program and the Division of Cognition and Emotion

The primary aim of his work is to understand individual differences in the response to treatments for depression so that more efficient and effective treatments can be developed. Work in his lab integrates tools from research on individual differences, treatment, and affective neuroscience to identify patient characteristics that are prognostic and prescriptive indicators of treatment response; to describe the markers of neural function associated with those indicators; and to develop and refine treatment strategies that better target the specific mechanisms that maintain an individual patient's illness.

Lisa Harding, MD | Advanced Treatments, Limited Reach: Access in Interventional Psychiatry
Assistant Clinical Professor
Department of Psychiatry, Yale School of Medicine

Lisa Harding, MD, is a board-certified psychiatrist and depression expert specially trained in providing all treatment types for depression. She is a graduate of the Yale School of Medicine where she finished her training as the Chief Resident of Intervention Psychiatric Services at Yale Psychiatric Hospital and is now Assistant Clinical Professor in the Department of Psychiatry at the Yale School of Medicine. She has personally completed over 4000 procedures which include administering ECT, rTMS, Esketamine and Ketamine. Dr Harding is the Medical Director of the Mood Institute, private insurance-based outpatient psychiatric practices, dedicated to treatment-resistant depression (TRD), especially in underserved populations.

Manish Jha, MD | Building the Bridge Between Primary Care and Interventional Psychiatry: How Can Measurement-Based Care Help? 
Associate Professor, Center for Depression Research and Clinical Care (CDRC)
O’Donnell Clinical Neuroscience Scholar at UT Southwestern Medical Center

He received his medical degree from Maulana Azad Medical College in New Delhi, India and completed his residency training in Psychiatry at UT Southwestern Medical Center, Dallas, TX.  In his clinical practice, he provides care to individuals with treatment-refractory mood disorders and substance use disorders. His research is focused on developing novel interventions for psychiatric disorders, personalizing the use of currently available treatments, and bringing these scientific discoveries to clinical practice. He is currently the PI of a NIMH-funded career development award (K23) to elucidate the neurocircuit mechanisms of irritability in adults with MDD that uses ketamine as a pharmacological probe.

Jordan Karp, MD
Chair of the Department of Psychiatry
Professor of Psychiatry, University of Arizona
Medical Director, Behavioral Health Technology, Banner Health

He is an expert in the fields of geriatric psychiatry, depression treatment, and suicide prevention. Dr. Karp’s priorities for the Department include: providing the best care possible to our patients and their families today; preparing the next generation of psychiatrists to provide better care in the future; produce the advancements in knowledge required to improve our ability to diagnose, treat, and ultimately prevent mental illness; and engage with diverse stakeholders to assure our workforce represents and meets the needs of our community and promotes social justice.

Eric Lenze, MD | Managing Late Life Depression in the Era of Clinical Complexity
Director, Healthy Mind Lab
​Professor and Chair of the Department of Psychiatry, Washington University School of Medicine

Dr. Lenze is renowned for his research in depression, anxiety, and cognitive functioning in older adults.  Among his more than 350 publications are studies published in JAMA, the New England Journal of Medicine, and the Lancet. He is a leader in cutting-edge clinical trial designs.  In 2020, he led a team that showed the drug fluvoxamine could prevent deterioration in acute COVID illness.  His team is now testing treatment for long COVID, to find help for neuropsychiatric symptoms such as “brain fog.” In his new study in long COVID patients, patients participate remotely via their smartphones; this speeds up recruitment and improves the quality of outcome measurement. Dr. Lenze’s research aims at reducing the negative outcomes of mental illness such as premature age-related morbidity.  He is testing senolytic drugs to “turn back the clock on aging” in individuals with depression and other illnesses associated with accelerated aging (such as schizophrenia). 

Samantha Meltzer-Brody, MD, MPH | Neurosteroids and Postpartum Depression: The Brexanolone and Zuranolone Journey from Bench to Bedside
Assad Meymandi Distinguished Professor
Chair of the Department of Psychiatry, University of North Carolina at Chapel Hill
Director, UNC Center for Women’s Mood Disorders.

She is a passionate advocate for innovation and transformation of mental health care. Dr. Meltzer-Brody is an internationally recognized physician-scientist in perinatal depression. Her research investigates the epidemiologic and biological predictors of perinatal depression and innovative treatment approaches (pharmacologic and psychotherapeutic), which have taken her across the globe including to sub-Saharan Africa. She had led the MOMS GENES study—the largest global genetic study of postpartum depression (PPD) using app-based tools. She served as the academic PI for novel psychopharmacologic clinical trials to develop the first FDA approved medication for postpartum depression (brexanolone), and served as an investigator for the newly approved oral drug (zuranolone) for PPD.

David C. Mohr, PhD | Digital Mental Health for Depression
Director, Center for Behavioral Intervention Technologies (CBITs)
Professor, Northwestern University’s Feinberg School of Medicine

Dr. Mohr’s research lies at the intersection of behavioral science, technology, and clinical research, focusing on the design, evaluation, and implementation of digital mental health technologies and services. He has developed and evaluated numerous web-based, mobile, and text messaging interventions for depression and anxiety. Dr. Mohr has also conducted research in personal sensing, using smartphone sensor data to detect behaviors related to common mental health problems such as depression and anxiety.  The goal of this work is to develop more efficient tools that can respond to sensed states to provide just-in-time interventions. Dr. Mohr is President of the Society for Digital Mental Health and a Fellow of the American Psychological Association and the Society for Behavioral Medicine.  His research has been consistently funded for more than 30 years by the NIH, other federal agencies, and numerous foundations, resulting in over 350 peer-reviewed publications, and more than 25 book chapters.

Patricio Riva Posse, MD | The Case for Surgical Neuromodulation Options in Treatment-Resistant Depression 
Director, Interventional Psychiatry Service and of the Treatment-Resistant Depression (TRD) Clinic
Associate Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine

Patricio Riva Posse, MD is a dual-trained neurologist and psychiatrist. His clinical activities involve treatments with ketamine/esketamine and non-invasive neuromodulation, such as ECT and rTMS. He provides consultation services in the TRD clinic. His research activities also incorporate invasive neuromodulation for psychiatric disorders, including Vagus Nerve Stimulation and Deep Brain Stimulation. He has led the clinical management of patients in DBS for depression protocols for the last 12 years. Partnering with neuroimaging researchers, biomedical engineers, and electrophysiologists, his ongoing research is focused on the identification of biomarkers of response to DBS. He is in the steering committee of the upcoming multicenter randomized clinical trial evaluating the efficacy of subcallosal cingulate DBS for depression. He teaches a monthly course for physicians interested in practicing ECT and ketamine/esketamine, and has been the co-director of the Interventional Psychiatry Fellowship since 2023. 

Sanjay J. Mathew, MD | EEG Gamma Oscillations as a Prognostic Marker for IV Ketamine in Treatment-Resistant Depression
Director, Mood & Anxiety Disorders Program
Professor and Vice Chair for Research, Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine

Dr. Sanjay also serves as a staff physician at the Michael E. Debakey VA Medical Center in Houston and a Senior Scientist at The Menninger Clinic. He graduated from Dartmouth College and Baylor College of Medicine, and trained as a resident in psychiatry at Columbia University/New York-Presbyterian Hospital.   He completed a postdoctoral research fellowship in mood and anxiety disorders at Columbia University and the New York State Psychiatric Institute. Prior to his current position, he served as faculty at the Icahn School of Medicine at Mount Sinai, where he co-directed the Mood & Anxiety Disorders Program. His research program, funded by NIH, VA, PCORI, and industry, focuses on experimental therapeutics and pathophysiology related to treatment-resistant mood/anxiety disorders and PTSD, with a particular focus on developing rapid-acting and novel pharmacotherapies. His program employs multiple neuroimaging techniques to uncover potential biomarkers associated with clinical outcomes.  

Ilse Wiechers, MD, MPP, MHS | Algorithms for TRD Treatment Success:  Lessons from the Veterans Health Administration
Associate Professor, University of California San Francisco
Associate Professor, Yale University School of Medicine

Dr. Wiechers is a practicing, board-certified adult and geriatric psychiatrist and a senior healthcare executive with the Department of Veterans Affairs. She serves as the Deputy Executive Director in VHA Office of Mental Health (OMH). In this role, she leads the operations of OMH and the timely development and implementation of policies and programs that ensure Veteran-centered, evidence-based, high-quality mental health services to over 1.9 million Veterans every year.  She also leads OMH’s legislative policy and partnership work, engaging regularly with key Congressional stakeholders and Veteran Service Organizations. She has been instrumental in the development of VHA’s portfolio of innovative mental health treatments including ketamine, esketamine, and psychedelic-assisted therapy

Nolan Williams, MD | Interventional Neuropsychiatry
Associate Professor, Stanford University
Director, Stanford Brain Stimulation Lab. 

The long-term goals of his research program are to develop innovative technologies and therapeutics capable of modulating the neural circuitry disrupted in mood disorders, OCD, and other neuropsychiatric conditions. His team has been developing neuroimaging-based approaches to precisely target therapeutic delivery and predict treatment responses to therapeutic neuromodulation and psychedelics. Dr. Williams earned his M.D. and completed his dual residencies in neurology and psychiatry at the Medical University of South Carolina (MUSC). Triple board-certified in general neurology, general psychiatry, as well as behavioral neurology and neuropsychiatry, Dr. Williams brings a comprehensive background in clinical neuroscience to his role as a clinically active neuropsychiatrist. His expertise extends to the development and implementation of novel therapeutics, including devices and novel compounds, for central nervous system illnesses.